<?xml version='1.0' encoding='UTF-8'?>
<rss xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" version="2.0"><channel><title>My Biopharma News Feed</title><link>http://yourdomain-or-some-place.com/custom_feed.xml</link><description>Daily curated &amp; AI-summarized biopharma news.</description><atom:link href="http://yourdomain-or-some-place.com/custom_feed.xml" rel="self"/><docs>http://www.rssboard.org/rss-specification</docs><generator>python-feedgen</generator><language>en</language><lastBuildDate>Fri, 07 Mar 2025 01:50:32 +0000</lastBuildDate><item><title>Trump administration policies could create headwinds across healthcare: Fitch</title><link>https://www.biopharmadive.com/news/trump-administration-policies-create-headwinds-healthcare-fitch-ratings/741615/</link><description>Fitch warns that new administration initiatives could jeopardize credit ratings for major drugmakers and other corporations, citing potential financial risks from policy changes. The report highlights concerns over how these measures might destabilize sectors reliant on current regulatory and fiscal frameworks.</description><pubDate>Tue, 04 Mar 2025 16:00:00 -0500</pubDate></item><item><title>Jazz expands in oncology with $935M deal for Chimerix</title><link>https://www.biopharmadive.com/news/jazz-chimerix-acquisition-cancer-drug-dordaviprone/741636/</link><description>Chimerix is awaiting an urgent FDA decision on accelerated approval for its experimental drug targeting a rare, aggressive form of brain cancer called glioma. The outcome could fast-track a promising new treatment for patients facing limited options, with the biopharma company and medical community eagerly anticipating the regulator’s verdict.</description><pubDate>Wed, 05 Mar 2025 11:53:00 -0500</pubDate></item><item><title>Tris to ask for approval of dual-acting pain drug</title><link>https://www.biopharmadive.com/news/tris-pain-drug-data-fda-approval-filing-plans/741727/</link><description>Promising results from two recent acute pain trials have bolstered confidence in a novel drug's unique mechanism, positioning it as a potential breakthrough in pain management. The company behind the treatment believes the differentiated approach could pave the way for regulatory approval and market success.</description><pubDate>Thu, 06 Mar 2025 09:30:00 -0500</pubDate></item><item><title>Amgen readies pivotal MariTide trials; Novo offers discounted Wegovy</title><link>https://www.biopharmadive.com/news/amgen-maritide-trials-duchenne-base-editing-wegovy-discount/741651/</link><description>&lt;figure&gt;&lt;div&gt;&lt;img src="https://imgproxy.divecdn.com/idsdMAHsPbXObDUtQW2qRG7uveBUVv6HCTn9NTtlDOI/g:nowe:0:0/c:1207:682/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNDgzOTIxNzkzLmpwZw==.webp" /&gt;&lt;/div&gt;&lt;/figure&gt;&lt;p&gt;Phase ...</description><pubDate>Thu, 06 Mar 2025 10:06:00 -0500</pubDate></item><item><title>Federal judge extends block on Trump plan to limit NIH payouts</title><link>https://www.biopharmadive.com/news/biotech-nih-funding-indirect-costs-trump-preliminary-injunction/741733/</link><description>A federal judge has blocked the Biden administration's proposal to limit indirect cost reimbursements for NIH grants, dealing a significant blow to a policy that aimed to redirect research funding. The ruling preserves critical financial support for universities and research institutions, which the pharmaceutical industry relies on for groundbreaking drug development and innovation.</description><pubDate>Thu, 06 Mar 2025 11:16:00 -0500</pubDate></item><item><title>Makary, under review to run FDA, evades pressure to reinstate canceled vaccine meeting</title><link>https://www.biopharmadive.com/news/makary-senate-hearing-fda-vaccines-meeting/741765/</link><description>President Trump's FDA nominee pledged during his Senate confirmation hearing to reevaluate which scientific topics require input from independent advisory committees. The move aims to address debates over the agency’s balance between expert guidance and regulatory efficiency, signaling potential shifts in how critical decisions are informed.</description><pubDate>Thu, 06 Mar 2025 12:30:00 -0500</pubDate></item><item><title>Following FDA cuts, Trump nominee Makary vows ‘independent’ staff review</title><link>https://www.biopharmadive.com/news/makary-hearing-fda-staffing-review-layoffs/741807/</link><description>A Johns Hopkins surgeon addressed the FDA's rapid expansion, emphasizing that despite growth, critical staff will receive "all the resources they need to do their job well." The assurance aims to balance scaling efforts with sustained operational effectiveness, prioritizing support for teams handling key responsibilities.</description><pubDate>Thu, 06 Mar 2025 15:42:00 -0500</pubDate></item><item><title>Vertex’s new pain drug gets first coverage nod from major insurer</title><link>https://www.biopharmadive.com/news/vertex-journavx-optum-united-health-coverage-tier-3/741850/</link><description>Optum, a UnitedHealth Group subsidiary, has temporarily added Journavx to some of its commercial drug coverage lists as an interim decision amid an ongoing formal review. The move allows immediate access to the medication while the company continues evaluating its long-term formulary status.</description><pubDate>Thu, 06 Mar 2025 17:59:00 -0500</pubDate></item><item><title>Transforming Early Detection in Oncology and Rare Diseases Using AI</title><link>https://www.fiercebiotech.com/premium/webinar/1368565</link><description>AI is transforming oncology and rare disease care by enabling early detection through analysis of unstructured data, helping healthcare systems deliver efficient, cost-effective treatment. Join experts Chris Tackaberry and Dr. Will Ricketts in this webinar to explore real-world AI applications, clinical case studies from ASCO and Nature, and strategies to improve diagnosis and patient outcomes.</description><pubDate>Mon, 24 Feb 2025 14:53:21 +0000</pubDate></item><item><title>The Oncology Market: 2025 Outlook</title><link>https://www.fiercebiotech.com/resource/oncology-market-2025-outlook</link><description>The oncology market is poised for transformative changes by 2025, driven by four key trends reshaping innovations, therapies, and global market dynamics. Dive into Blue Matter Consulting’s whitepaper to explore how emerging technologies and strategic shifts will redefine cancer treatment and industry landscapes in the years ahead.</description><pubDate>Tue, 25 Feb 2025 14:49:58 +0000</pubDate></item><item><title>Redefining vaccine trial recruitment</title><link>https://www.fiercebiotech.com/resource/redefining-vaccine-trial-recruitment</link><description>Avacare Clinical Research Network highlights the critical need for innovative, data-driven strategies to overcome recruitment challenges and ensure diverse, efficient vaccine trials in their latest white paper. Discover actionable insights to enhance trial quality and inclusivity by accessing their exclusive resource here: https://bit.ly/3QxgZcR.</description><pubDate>Wed, 26 Feb 2025 14:26:35 +0000</pubDate></item><item><title>Using Client Centricity as Fuel for Innovative Biologics Development and Manufacturing Solutions</title><link>https://www.fiercebiotech.com/resource/using-client-centricity-fuel-innovative-biologics-development-and-manufacturing-solutions</link><description>Rentschler Biopharma's latest whitepaper underscores the value of client-centric strategies in advancing innovative biologics development and manufacturing, offering actionable insights to optimize processes while maintaining high-quality standards. Tailored for biopharma professionals—from process scientists to executives—it serves as a guide to modern solutions that balance efficiency and excellence in a rapidly evolving industry.</description><pubDate>Tue, 04 Mar 2025 16:39:29 +0000</pubDate></item></channel></rss>
